FOXO4-DRI
Senolytic Peptide — Selective Apoptosis of Senescent Cells
Molecular Data
- Formula
- C168H258N44O49S
- Molecular Weight
- 3856.1 g/mol
01
Overview
FOXO4-DRI is a synthetic D-retro-inverso peptide designed to disrupt the interaction between FOXO4 and p53 in senescent cells. Developed at the Erasmus MC Medical Center in Rotterdam, it represents a senolytic approach that selectively induces apoptosis in cells that have entered replicative senescence while sparing healthy proliferating cells.
02
Mechanism of Action
In senescent cells, FOXO4 binds p53 and sequesters it in the nucleus, preventing apoptosis. FOXO4-DRI displaces p53 from FOXO4 by competing for the FOXO4 binding interface, freeing p53 to translocate to mitochondria and initiate apoptosis. Because only senescent cells accumulate FOXO4, healthy cells are unaffected.
03
Research Highlights
Erasmus MC research demonstrates reversal of chemotoxicity-induced alopecia and frailty in mice
Progeroid mouse models show restored renal function, fur density, and physical activity
In vitro senescence assays confirm selective apoptosis of senescent cells versus controls
04
Dosage
Administration & Timing
Subcutaneous (SC) injection into abdominal or gluteal subcutaneous tissue, typically once daily for short pulses. Research protocols in animal senescence models use brief courses.
Dosage Guidelines
Cycle Length
3–5 day pulse; repeat monthly in senolytic research.
05
Reconstitution
Solvent
Bacteriostatic Water (0.9% benzyl alcohol)
Volume
2 mL added to a 50 mg vial
Concentration
25 mg/mL
Storage
Lyophilized powder: store at -20 °C long-term. Reconstituted: refrigerate 2–8 °C, use within 30 days.
Notes
FOXO4-DRI is a D-retro-inverso peptide that disrupts FOXO4-p53 binding to clear senescent cells. Preclinical — no published human data.
Research Reference Only
Dosage and reconstitution values reflect commonly cited ranges from published research literature and are presented for educational and research reference only. This is not medical advice or a dosing recommendation. HEXAGEN does not endorse human use of any compound. Always consult a qualified healthcare professional.
Research Disclaimer
FOXO4-DRI is for educational and research purposes only. Not intended as medical advice. Consult a qualified healthcare professional before making any health-related decisions.
Related Compounds
View All
FOXO4-DRI Knowledge Graph
Explore how FOXO4-DRI connects to mechanisms, research goals, related compounds, research stacks, and scientific references. Drag nodes, zoom, and filter by type.
No nodes match the active filters.
FOXO4-DRI — Common Research Questions
What is FOXO4-DRI?
FOXO4-DRI is a synthetic D-retro-inverso peptide designed to disrupt the interaction between FOXO4 and p53 in senescent cells. Developed at the Erasmus MC Medical Center in Rotterdam, it represents a ... FOXO4-DRI belongs to the Anti Aging research category and is studied for its senolytic peptide — selective apoptosis of senescent cells.
How does FOXO4-DRI work?
In senescent cells, FOXO4 binds p53 and sequesters it in the nucleus, preventing apoptosis. FOXO4-DRI displaces p53 from FOXO4 by competing for the FOXO4 binding interface, freeing p53 to translocate to mitochondria and initiate apoptosis. Because only senescent cells accumulate FOXO4, healthy cells are unaffected.
What are the key research benefits of FOXO4-DRI?
Selective elimination of senescent cells. Reversal of age-related functional decline in research models. Renal function restoration in progeroid mice. Coat density and activity restoration in aged animals. Spares healthy cells via p53 pathway selectivity. Demonstrated senolytic efficacy in vivo.
What is the molecular structure of FOXO4-DRI?
FOXO4-DRI has the molecular formula C168H258N44O49S and a molecular weight of 3856.1 g/mol. This structural information is important for researchers studying receptor binding and pharmacokinetics.
What does the research say about FOXO4-DRI?
Erasmus MC research demonstrates reversal of chemotoxicity-induced alopecia and frailty in mice Progeroid mouse models show restored renal function, fur density, and physical activity In vitro senescence assays confirm selective apoptosis of senescent cells versus controls These findings are based on preclinical and clinical research. FOXO4-DRI is a research compound and these studies do not constitute medical advice.
Is FOXO4-DRI FDA approved?
No. FOXO4-DRI is not FDA-approved for any indication. It is a research chemical studied in preclinical and early clinical research. These compounds are not approved for human therapeutic use and should only be studied in appropriate research settings.
What category does FOXO4-DRI belong to?
FOXO4-DRI belongs to the Anti Aging category, which focuses on peptides researched for their telomere-supporting, mitochondrial-protective, and senolytic properties aligned with healthy longevity science. You can explore more compounds in this category on the Anti Aging pillar page.
Related Articles
Epitalon: Telomerase Activation and Lifespan Research
35 years of Russian research on Epitalon's telomere-elongating effects and the landmark gerontology studies.
SS-31 (Elamipretide): Mitochondrial Cardiolipin Protection
How SS-31 stabilizes the inner mitochondrial membrane and its Phase II heart failure trial data.
MOTS-c: The Mitochondrial-Derived Peptide
USC research on MOTS-c's role in insulin sensitivity, metabolic homeostasis, and exercise mimetic effects.
Scientific References
Erasmus MC research demonstrates reversal of chemotoxicity-induced alopecia and frailty in mice
Progeroid mouse models show restored renal function, fur density, and physical activity
In vitro senescence assays confirm selective apoptosis of senescent cells versus controls